WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq:INCY) today announced that multiple abstracts highlighting data from its oncology portfolio will be presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting, held from November 10-14, 2021 in Washington, D.C and virtually.

“We look forward to presenting data from multiple programs within Incyte's immuno-oncology portfolio at this year’s SITC conference,” said Lance Leopold, M.D., Group Vice President, Immuno-Oncology, Incyte. “Data being presented from the retifanlimab POD1UM clinical program, including a late-breaking poster presentation highlighting results from the POD1UM-101 study; as well as results from a Phase 1 study evaluating an oral PD-L1 inhibitor in immune-checkpoint naïve patients with advanced solid tumors, demonstrate our commitment to addressing the needs of patients with historically difficult-to-treat cancers.”

Key abstracts include:

**Late-Breaking Poster Presentation**

Retifanlimab (INCMGA00012) in patients with recurrent MSI-H or dMMR endometrial cancer: Results from the POD1UM-101 Study (Abstract #956. Saturday, November 13, 7:00 a.m. – 8:30 p.m. ET)

**Oral Presentation**

Phase 1 study of INCB086550, an oral PD-L1 inhibitor, in immune-checkpoint naive patients with advanced solid tumors (Abstract #529. Session: Concurrent Rapid Oral Abstract Presentation: Clinical.)
Saturday, November 13, 12:45 – 1:45 p.m. ET

**Poster Presentation**

A Phase 2 Study of Retifanlimab in Patients With Advanced or Metastatic Merkel Cell Carcinoma (MCC) (POD1UM-201) (Abstract #545. Friday, November 12, 7:00 a.m. – 8:30 p.m. ET)

Full abstracts will be available on the SITC website and in the Journal for ImmunoTherapy of Cancer (JITC) on November 9, 2021. More information regarding the conference is available on the SITC website: [https://www.sitcancer.org/2021/home](https://www.sitcancer.org/2021/home).

**Conference Call and Webcast**

Incyte will host an analyst and investor conference call and webcast on Saturday, November 13, 2021 from 6:30 – 7:30 p.m. ET to discuss its oral PD-L1 clinical development program, including data from INCB86550 which has been accepted for oral presentation at the SITC Annual Congress.

The live and archived webcast will be available via [investor.incyte.com](http://investor.incyte.com).

To access the conference call, please dial 877-407-3042 for domestic callers or +1-201-389-0864 for international callers (conference identification number 13724808). If you are unable to participate, a replay will be available for 30 days. The replay dial-in number for the United States is 877-660-6853 and the dial-in number for international callers is +1-201-612-7415 (conference identification number 13724808).

**About Incyte**

Incyte is a Wilmington, Delaware-based, global biopharmaceutical company focused on finding solutions for serious unmet medical needs through the discovery, development and commercialization of proprietary therapeutics. For additional information on Incyte, please visit [Incyte.com](http://Incyte.com) and follow @Incyte.

**Forward-Looking Statements**

Except for the historical information set forth herein, the matters set forth in this press release, including statements regarding the Company’s ongoing clinical development pipeline, its presentation plans for the upcoming SITC meeting and its goal of improving the lives of patients and finding solutions to unmet medical needs, contain predictions, estimates and other forward-looking statements.

These forward-looking statements are based on the Company’s current expectations and subject to risks and
uncertainties that may cause actual results to differ materially, including unanticipated developments in and risks related to: unanticipated delays; further research and development and the results of clinical trials possibly being unsuccessful or insufficient to meet applicable regulatory standards or warrant continued development; the ability to enroll sufficient numbers of subjects in clinical trials; the effects of the COVID-19 pandemic and measures to address the pandemic on the Company’s clinical trials, supply chain, other third-party providers and development and discovery operations; determinations made by the U.S. FDA and other regulatory authorities outside of the United States; the efficacy or safety of the Company’s products; the acceptance of the Company’s products in the marketplace; market competition; sales, marketing, manufacturing and distribution requirements; and other risks detailed from time to time in the Company’s reports filed with the Securities and Exchange Commission, including its annual report and its quarterly report on Form 10-Q for the quarter ended June 30, 2021. The Company disclaims any intent or obligation to update these forward-looking statements.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211101005607/en/

Media
Catalina Loveman
+1 302 498 6171
cloveman@incyte.com

Investors
Christine Chiou
+1 302 274 4773
cchiou@incyte.com

Source: Incyte